Introduction

Atrial fibrillation (AF) is the most common cardiac arrhythmia and the incidence and prevalence of this disease are rising.1 2 It is estimated that by the year 2050 there will be over 7.5 million patients with AF in the USA alone.3 This disease carries a significant risk of morbidity and mortality driven in large part by the development of heart failure and thromboembolism.4 Oral anticoagulation therapy is effective in reducing risk of stroke and systemic embolism and is the standard of care for patients undergoing either a rhythm or rate control strategy.

For years warfarin has been the mainstay of stroke prophylaxis. More recently, direct-acting oral anticoagulants (DOACs) have entered the marketplace.5 Their site of action within the coagulation cascade is outlined in figure 1.6 7 These newer agents have rapidly been incorporated into modern practice,8 though there remains a role for warfarin among various subgroups. Selecting an appropriate agent is a complex decision and must take account a patient’s comorbidities, preference for dosing and monitoring, concern over the lack of a specific antidote, and importantly, financial constraints.